Reforgene named a Future Healthcare Top 100 company for the fourth consecutive year

Recently, the 2026 Future Healthcare Top 100 conference hosted by VBDATA concluded successfully in Shanghai. The conference simultaneously released the authoritative "2026 Future Healthcare Top 100 (VB100)" series lists. Following consecutive listings from 2023 to 2025, Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene") once again entered the 2026 Innovative Medicine and Biologics TOP100, achieving its fourth consecutive listing. Four consecutive years of selection fully demonstrate Reforgene's deep accumulation and research strength in the innovative R&D of gene editing medicines, and represent the recognition by industry experts, industry observers and professional institutions of the company's technological barriers and innovative achievements.

With the theme of "Innovation, Trends, Synergy", this edition of the conference focused on frontier tracks including brain-computer interfaces, medical AI, synthetic biology, and the overseas expansion of pharmaceuticals and devices, bringing together heavyweight guests from government, academia, industry, investment and clinical fields to jointly explore the future development direction of China's healthcare industry.